enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 60,300 shares, a decrease of 31.9% from the February 13th total of 88,500 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 131,100 shares, the short-interest ratio is currently 0.5 days.

enGene Trading Up 0.9 %

enGene stock traded up $0.05 during midday trading on Friday, reaching $5.40. The stock had a trading volume of 23,426 shares, compared to its average volume of 131,979. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a 52-week low of $4.42 and a 52-week high of $18.40. The firm has a market cap of $275.28 million, a price-to-earnings ratio of -9.31 and a beta of -0.61. The company has a fifty day moving average of $6.51 and a 200 day moving average of $7.12.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. On average, analysts anticipate that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Trading of enGene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Deep Track Capital LP grew its stake in enGene by 74.8% in the 4th quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock worth $30,308,000 after acquiring an additional 1,949,942 shares in the last quarter. VR Adviser LLC grew its stake in enGene by 41.5% in the 4th quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after acquiring an additional 1,480,573 shares in the last quarter. Fcpm Iii Services B.V. grew its stake in enGene by 11.0% in the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock worth $64,057,000 after acquiring an additional 954,610 shares in the last quarter. Orbimed Advisors LLC bought a new position in enGene in the 4th quarter worth about $6,120,000. Finally, Point72 Asset Management L.P. grew its stake in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after acquiring an additional 619,100 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ENGN shares. Morgan Stanley decreased their price target on shares of enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of enGene in a research note on Tuesday, March 11th. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 target price on shares of enGene in a research note on Monday, December 23rd. UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and decreased their target price for the company from $34.00 to $7.00 in a research note on Friday, February 14th. Finally, Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.22.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.